Circulating Sclerostin in Disorders of Parathyroid Gland Function

被引:47
作者
Costa, Aline G. [1 ,2 ]
Cremers, Serge [1 ]
Rubin, Mishaela R. [1 ]
McMahon, Donald J. [1 ]
Sliney, James, Jr. [1 ]
Lazaretti-Castro, Marise [2 ]
Silverberg, Shonni J. [1 ]
Bilezikian, John P. [1 ]
机构
[1] Columbia Univ, Coll Phys & Surg, Dept Med, Div Endocrinol,Metab Bone Dis Unit, New York, NY 10032 USA
[2] Univ Fed Sao Paulo, Div Endocrinol, Dept Med, BR-04044 Sao Paulo, Brazil
基金
美国国家卫生研究院;
关键词
BONE-FORMATION; PRIMARY HYPERPARATHYROIDISM; WNT; HORMONE; SOST; OSTEOCYTES; PROTEIN; PTH; OSTEOMALACIA; EXPRESSION;
D O I
10.1210/jc.2011-0566
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Sclerostin, a protein encoded by the SOST gene in osteocytes and an antagonist of the Wnt signaling pathway, is down-regulated by PTH administration. Disorders of parathyroid function are useful clinical settings to study this relationship. Objective: The objective of the study was to evaluate sclerostin in two different disorders of parathyroid function, primary hyperparathyroidism and hypoparathyroidism, and to analyze the relationship between sclerostin and PTH, bone markers, and bone mineral density. Design: This is a cross-sectional study. Setting: The study was conducted at a clinical research center. Patients: Twenty hypoparathyroid and 20 hyperparathyroid patients were studied and compared to a reference control group. Results: Serum sclerostin was significantly higher in hypoparathyroid subjects than in hyperparathyroid subjects (P < 0.0001) and controls (P < 0.0001). PTH was negatively associated with sclerostin, achieving statistical significance in hypoparathyroidism (r = -0.545; P = 0.02). The bone turnover markers, cross-linked C-telopeptide of type I collagen (CTX) and amino-terminal propeptide of type I collagen (P1NP), were differently associated with sclerostin according to the parathyroid disorder. In primary hyperparathyroidism, bone turnover markers were associated negatively with sclerostin (for P1NP, r = -0.490; P = 0.03). In hypoparathyroidism, bone turnover markers were associated positively with sclerostin (for CTX, r = +0.571; P = 0.01). Although there was no significant correlation between bone mineral density and sclerostin in either parathyroid disorder, there was a significant positive relationship between sclerostin and bone mineral content in hypoparathyroidism. Conclusions: The results are consistent with the hypothesis that PTH is a regulator of sclerostin in human disorders of parathyroid function. In addition, the results suggest that bone mineral content may be another factor that influences sclerostin. (J Clin Endocrinol Metab 96: 3804-3810, 2011)
引用
收藏
页码:3804 / 3810
页数:7
相关论文
共 34 条
  • [1] Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
    Balemans, W
    Ebeling, M
    Patel, N
    Van Hul, E
    Olson, P
    Dioszegi, M
    Lacza, C
    Wuyts, W
    Van den Ende, J
    Willems, P
    Paes-Alves, AF
    Hill, S
    Bueno, M
    Ramos, FJ
    Tacconi, P
    Dikkers, FG
    Stratakis, C
    Lindpaintner, K
    Vickery, B
    Foernzler, D
    Van Hul, W
    [J]. HUMAN MOLECULAR GENETICS, 2001, 10 (05) : 537 - 543
  • [2] Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis
    Bellido, T
    Ali, AA
    Gubrij, I
    Plotkin, LI
    Fu, Q
    O'Brien, CA
    Manolagas, SC
    Jilka, RL
    [J]. ENDOCRINOLOGY, 2005, 146 (11) : 4577 - 4583
  • [3] SOST/sclerostin, an osteocyte-derived negative regulator of bone formation
    Bezooijen, RL
    ten Dijke, P
    Papapoulos, SE
    Löwik, CWGM
    [J]. CYTOKINE & GROWTH FACTOR REVIEWS, 2005, 16 (03) : 319 - 327
  • [4] Osteocytes, mechanosensing and Wnt signaling
    Bonewald, Lynda F.
    Johnson, Mark L.
    [J]. BONE, 2008, 42 (04) : 606 - 615
  • [5] Effects of Parathyroid Hormone Treatment on Circulating Sclerostin Levels in Postmenopausal Women
    Drake, Matthew T.
    Srinivasan, Bhuma
    Moedder, Ulrike I.
    Peterson, James M.
    McCready, Louise K.
    Riggs, B. Lawrence
    Dwyer, Denise
    Stolina, Marina
    Kostenuik, Paul
    Khosla, Sundeep
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (11) : 5056 - 5062
  • [6] Increased Sclerostin Serum Levels Associated with Bone Formation and Resorption Markers in Patients with Immobilization-Induced Bone Loss
    Gaudio, Agostino
    Pennisi, Pietra
    Bratengeier, Cornelia
    Torrisi, Venerando
    Lindner, Brigitte
    Mangiafico, Roberto A.
    Pulvirenti, Ivana
    Hawa, Gerhard
    Tringali, Giovanni
    Fiore, Carmelo E.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (05) : 2248 - 2253
  • [7] Cinacalcet in the management of tumor-induced osteomalacia
    Geller, Jordan L.
    Khosravi, Azarmindokht
    Kelly, Marilyn H.
    Riminucci, Mara
    Adams, John S.
    Collins, Michael T.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 (06) : 931 - 937
  • [8] FGF-23 is elevated by chronic hyperphosphatemia
    Gupta, A
    Winer, K
    Econs, MJ
    Marx, SJ
    Collins, MT
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (09) : 4489 - 4492
  • [9] The natural history of sclerosteosis
    Hamersma, H
    Gardner, J
    Beighton, P
    [J]. CLINICAL GENETICS, 2003, 63 (03) : 192 - 197
  • [10] The Wnt signaling pathway and bone metabolism
    Johnson, Mark L.
    Kamel, Mohamed A.
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2007, 19 (04) : 376 - 382